You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》里昂料中國醫療健康行業流動性及基本面持續改善
里昂發表研究報告指,中國醫療健康行業流動性及基本面持續改善,維持對醫療健康板塊正面看法,指出美國就業數據疲軟或市場對下半年貨幣寬鬆預期急升溫,預視著行業下半年改善前景,相信特朗普再提最惠國藥品定價政策及安徽啟動生物類似藥集中採購,對行業影響則相對有限。 里昂指出,行業基本面持續復甦,7月院內處方量按月提升,隨著更多創新藥放量,第三季行業盈利有望實現顯著增長,加上美債不確定性可能促使資金重新配置,進一步改善創新藥資產流動性,相信行業拐點已過,未來將迎來盈喜等正面催化劑。 該行偏好領先大型藥廠,短期而言避開過度依賴生物仿製藥的公司。該行選股包括石藥集團(01093.HK)、新諾威(300765.SZ)、翰森製藥(03692.HK)、愛爾眼科(300015.SZ)、恆瑞醫藥(01276.HK)(600276.SH)、康方生物(09926.HK)、中生製藥(01177.HK)、國藥控股(01099.HK)、康哲藥業(00867.HK)、大參林(603233.SH)、華東醫藥(000963.SZ)、泰格醫藥(03347.HK)及藥明康德(02359.HK)。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account